摘要
目的 探讨氯吡格雷抵抗与ABCB1 3435C>T基因位点多态性关联性。方法 计算机检索Pubmed、Science direct、Wiley online library、Web of Science、中国知网、万方数据库和维普中文科技期刊数据库,纳入氯吡格雷抵抗与氯吡格雷有效的随机对照试验,同时查阅检索结果中所附相似文献及参考文献,检索文献均为建库至2014年6月25日,采用RevMan5.0软件进行Meta分析及其他统计学分析。 结果 共纳入文献6篇;患者中氯吡格雷抵抗2 619例、氯吡格雷有效2 799例。Meta分析结果显示,3435C>T位点多态性在等位基因模型、显性基因模型、共显性基因模型(CC/CT)和超显性基因模型下整体效应有统计学意义(P<0.05):等位基因模型OR=1.27,95%CI(1.13,1.42),显性基因模型OR=1.42,95%CI(1.22,1.65),共显性基因模型(CC/CT)OR=1.43,95%CI(1.20,1.69),超显性基因模型OR=1.30,95%CI(1.11,1.52)。人种亚组分析表明,欧洲地区ABCB1 3435C>T位点基因多态性与氯吡格雷抵抗均无统计学意义(P>0.05);而亚洲地区ABCB1 3435C>T位点基因多态性与氯吡格雷抵抗在等位基因模型、显性基因模型、共显性基因模型(CC/CT)和超显性基因模型下整体效应有统计学意义(P<0.05):等位基因模型OR=1.57,95%CI(1.34,1.84),显性基因模型 OR=2.11,95%CI(1.71,2.60)、共显性基因模型(CC/CT)OR=2.15,95%CI(1.72,2.69),超显性基因模型OR=1.82,95%CI(1.48,2.24)。结论 亚洲地区,ABCB1 3435C>T位点基因多态性与氯吡格雷抵抗有相关性,而在欧洲地区则无相关性。
Abstract
OBJECTIVE To investigate the association between clopidogrel resistance (CR) with 3435C>T site polymorphism of ABCB1 gene. METHODS The published articles were searched in the Pubmed, Science direct, Wiley online library, Web of Science, CNKI, CDDB database, and VIP. Search and sort out the article which is clopidogrel-resistance/clopidogrel-efficacy(CE) study about the relationship between CR and 3435C>T site polymorphism of ABCB1 gene, also combined with manually retrieving the references and similar results in the attached documents. The range of searching time was all from inception to June 25,2014. RevMan5.0 software was used to conduct the Meta-analysis and other statistic analysis. RESULTS Six articles were included in our research. It showed that the total number of CR is 2 619, and the total number of CE is 2 799. While the result showed that there exist significant correlations between ABCB1 3435C>T loci polymorphism and CR in the allele gene model, dominant gene model, co-dominant gene model(CC/CT) and super-dominant gene model:the allele gene model, OR=1.27,95%CI(1.13,1.42); dominant gene model, OR=1.42,95%CI(1.22,1.65); co-dominant gene model(CC/CT), OR=1.43,95%CI(1.20,1.69); super-dominant gene model, OR=1.30,95%CI(1.11,1.52). The further race subgroup analysis showed that there possess significant relevance between ABCB1 3435C>T loci polymorphism and CR in Asia (P<0.05), but not in Europe. In the allele gene model, OR=1.57,95%CI(1.34,1.84); dominant gene model, OR=2.11,95%CI(1.71,2.60); co-dominant gene model(CC/CT), OR=2.15,95%CI(1.72,2.69); super-dominant gene model, OR=1.82,95%CI(1.48,2.24). CONCLUSION CR dose not relate to the ABCB1 3435C>T loci polymorphism among European; but CR relates to the ABCB1 3435C>T loci polymorphism among Asian.
关键词
氯吡格雷抵抗 /
ABCB1 /
3435C> /
T /
基因多态性 /
Meta分析
{{custom_keyword}} /
Key words
clopidogrel resistance /
ABCB1 /
3435C> /
T /
polymorphism /
Meta-analysis
{{custom_keyword}} /
彭锐,张洪,张英,魏丹芸.
氯吡格雷抵抗与ABCB1 3435C>T基因位点多态性的Meta分析[J]. 中国药学杂志, 2015, 50(10): 909-912 https://doi.org/10.11669/cpj.2015.10.020
PENG Rui, ZHANG Hong, ZHANG Ying, WEI Dan-yun.
Clopidogrel Resistance and ABCB1 (3435C>T) Gene Polymorphism:A Meta Analysis[J]. Chinese Pharmaceutical Journal, 2015, 50(10): 909-912 https://doi.org/10.11669/cpj.2015.10.020
中图分类号：
R968
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] KING S B, SMITH S C, HIRSHFELD J W, et al. Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Cororary Intervention:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Eur Heart J, 2008, 117(6):261-295.
[2] WANG X, ZHANG Y, XUE C, et al. The secondary prevention guide of ischemic stroke and transient ischemic attack in China. Chin J Neurol(中华神经科杂志), 2010, 43(4):154-160.
[3] KULICZKOWSKI W, WITKOWSKI A, POLONSKI L, et al. Interindividual variability in the response to oral antiplatelet drugs:a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J, 2009,30(4):426-435.
[4] MATETZKY S, SHENKMAN B, GUETTA V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation, 2004, 109(8):3171-3175.
[5] PRICE M J. Bedside evaluation of thienopyridine antiplatelet therapy. Circulation, 2009, 119(15):2625-2632.
[6] FORD N F. Clopidogrel resistance:pharmacokinetic or pharmacogenetic. J Clin Pharmacol, 2009,49(5):506-512.
[7] SIMON T, VERSTUYFT C, MARY-KRAUSE M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med, 2009,360(4):363-375.
[8] SAKAEDA T, NAKAMURA T, OKUMURA K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull, 2002,25(11):1391-1400.
[9] KAVITA K S, VINOD K S, POONAM P, et al. Polymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population:Effects on clopidogrel response. India Heart J,2013 ,65(14):158-167.
ZHANG L, CHEN Y M, JIN Y, et al. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients. Thrombosis Res,2013,132(3):81-87.
WANG X D, ZHANG D F, LIU X B, et al. Modified clopidogrel loading dose according to platelet reactivity monitoring in patients carrying ABCB1 variant alleles in patients with clopidogrel resistance. Eur J Int Med, 2012,23(8):48-53.
JULIANE J, TANJA M, ROBERT A B, et al. No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting. Circ Cardiovasc Interv, 2012,5(14):82-88.
TABASSOME S I, CELINE V, MURIELLE M K, et al. Genetic Determinants of Response to clopidogrel and Cardiovascular Events. N Engl J Med, 2009,360(4):363-375.
BAI J. The study in the association between ABCB1 polymorphisms and clopidogrel resistance. Respir Res, 2012, 14(8):32-43.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(1041 KB)
